Jan 09, 2023 / 05:45PM GMT
Anupam Rama - JPMorgan Chase & Co, Research Division - VP and Analyst
Okay. Let's get started. Welcome to the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan.
I am joined by my team, Priyanka Grover and Malcolm Kuno. Our next presenting company is Replimune, and presenting on behalf of the company, we have the CEO. Philip?
Philip Astley-Sparke - Replimune Group, Inc. - CEO & Director
Thanks, Anupam. Replimune. Replimune is the industry leader in tumor-directed oncolytic immunotherapy. We have 3 wholly owned programs, RP1, 2 and 3. RP1 data to date supports the emergence of a major skin cancer franchise.
We have 2 registrational studies ongoing. The first is in frontline cutaneous squamous cell carcinoma, where in a prior single-arm study, we showed a very impressive almost 1 in 2 complete response rate.
We have subsequently fully enrolled a 211-patient randomized controlled study of RP1 plus cemiplimab standard of care against
Replimune Group Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers